Form 4: Leon O. Moulder Jr., Director at Dianthus Therapeutics, Acquires 11,000 Stock Options

Director Leon O. Moulder Jr. reports acquisition of 11,000 stock options in Dianthus Therapeutics.

Summary

• On May 23, 2024, Leon O. Moulder Jr., a director of Dianthus Therapeutics, Inc., acquired 11,000 stock options.
• The exercise price for these options is $21.77.
• The options vest on the earlier of the first anniversary of the grant date or the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service.
• The options expire on May 22, 2034.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative performance.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the pharmaceutical industry. It provides transparency regarding the holdings and transactions of company directors.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, especially in the biotech and pharmaceutical sectors, to align their interests with those of shareholders.
• The vesting schedule, contingent on continued service, is standard practice to incentivize long-term commitment.
• Comparable companies like Amgen, Gilead Sciences, and Biogen also regularly grant stock options to their directors as part of their compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director can signal confidence in the company's future prospects, potentially positively influencing shareholder sentiment.

Key Dates